FDA Puts Hold on Esophagitis, H pylori Drug FDA Puts Hold on Esophagitis, H pylori Drug

The regulatory delays stem from the presence of trace levels of a nitrosamine impurity that were initially detected in launch materials for two vonoprazan products from Phathom Pharmaceuticals.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news